Superworth

EyePoint price to free cash flow EYPT

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
107×
Mar 2024
Peer median
11.8×

EyePoint's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Mar 2024, at 107×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2024107×78.2×110×
202388.6×17.5×88.6×
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
201610.3×10.3×12.1×
201514.7×9.2×14.7×

Against its peers

Companies in Healthcare nearest EyePoint's size, closest first, today.

CompanyPrice to free cash flow
EYPTEyePointn/m
NEPHNephrosn/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech9.7×
SPROSpero Therapeuticsn/m
LFVNLifevantage11.0×
ICCCImmucell22.1×
KEQUKewaunee Scientific8.7×
PDEXPro DEX29.5×
PLXProtalix BioTherapeutics26.8×
NATRNatures Sunshine Products11.8×
Peer median11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on EyePoint

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.